Wednesday, January 03, 2024 1:50:46 AM
1. See the end of year letter from COB Richard Staelin dated 12/22/23.
Here's what specifically he stated:
"Finally, we completed a new design for our RecoveryRx product that is better suited for surgery incisions and is 50% more powerful than the current version. We have already manufactured a limited supply of these units and are planning to apply for an expedited 510(k) from the FDA in the near future."
2. Also op cit letter dated 12/22/23 by COB Richard Staelin:
News on the sales front is more mixed. We brought in two new distributors for Bulgaria and the Netherlands and will relaunch in Australia in early 2024.
You can read his letter here:
https://finance.yahoo.com/news/end-message-chairman-board-bioelectronics-205500227.html
I did some research but can't find any performance specs, clinical-evidence trials going on etc about the new and improved RecoveryRx. The 50% enhanced version.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM